Subiaco-based drug development company Phylogica Ltd will allow the Swiss Institute of Allergy & Asthma Research to screen its libraries of proteins for potential vaccine leads under a research collaboration agreement, the company has announced.

Phylogica's Phylomer peptides are stable fragments of naturally-occurring proteins with the ability to bind tightly to target proteins and inactivate them as a result.